BioCryst Pharmaceuticals Ownership
| BCRX Stock | USD 7.50 0.01 0.13% |
Shares in Circulation | First Issued 1994-03-31 | Previous Quarter 206.4 M | Current Value 206.9 M | Avarage Shares Outstanding 62.5 M | Quarterly Volatility 59.5 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
BioCryst |
BioCryst Stock Ownership Analysis
About 86.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.61. BioCryst Pharmaceuticals had not issued any dividends in recent years. BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. Biocryst Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 358 people. For more info on BioCryst Pharmaceuticals please contact Jon Stonehouse at 919 859 1302 or go to https://www.biocryst.com.BioCryst Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as BioCryst Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BioCryst Pharmaceuticals backward and forwards among themselves. BioCryst Pharmaceuticals' institutional investor refers to the entity that pools money to purchase BioCryst Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Rock Springs Capital Management Lp | 2024-06-30 | 3.6 M | Fisher Asset Management, Llc | 2024-09-30 | 3.3 M | Gw&k Investment Management, Llc | 2024-09-30 | 3.3 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 3.2 M | Goldman Sachs Group Inc | 2024-06-30 | 2.5 M | Rice Hall James & Associates, Llc | 2024-09-30 | 2.2 M | Fmr Inc | 2024-09-30 | 2 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 1.9 M | Two Sigma Advisers, Llc | 2024-06-30 | 1.9 M | Vanguard Group Inc | 2024-09-30 | 20.3 M | Blackrock Inc | 2024-06-30 | 20 M |
BioCryst Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioCryst Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioCryst Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BioCryst Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
BioCryst Pharmaceuticals Outstanding Bonds
BioCryst Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. BioCryst Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most BioCryst bonds can be classified according to their maturity, which is the date when BioCryst Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BIO 33 15 MAR 27 Corp BondUS090572AR99 | View | |
| BIO 37 15 MAR 32 Corp BondUS090572AQ17 | View | |
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
BioCryst Pharmaceuticals Corporate Filings
13A | 7th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 5th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 4th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 3rd of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.